PRODUCT DETAILS VIEW ALL PRODUCTS

Neurocetam Injection (Piracetam ).

  • Each 15 ml & 60 ml of Neurocetam injection contains Piracetam BP 200 mg.
  • For the symptomatic treatment of adult patients suffering from myoclonus of cortical origin, irrespective of etiology, and should be used in combination with other anti-myoclonic therapies.
  • Piracetam binds physically in a dose-dependent manner to the polar head of phospholipids membrane models, inducing the restoration of the membrane lamellar structure characterized by the formation of mobile drug-phospholipid complexes. Improves membrane stability, allowing the membrane and transmembrane proteins to maintain or recover the three-dimensional structure or folding essential to exert their function. Piracetam has neuronal and vascular effects.
  • This is administered intravenously twice daily, but may also be given in three or four separate doses.
  • Hypersensitivity to piracetam, other pyrrolidone derivatives or any of the excipients, cerebral hemorrhage, Huntington's chorea and end-stage renal-disease.
  • Caution is recommended in patients with severe haemorrhage, patients at risk of bleeding, care should be taken in cases of renal insufficiency, avoid abrupt discontinuation, caution should be exercised by patients who are on a controlled sodium diet. For long-term treatment in the elderly, regular evaluation of the creatinine clearance is required to allow dosage adaptation if needed. Abrupt discontinuation of treatment should be avoided as this may induce myoclonic or generalised seizures in some myoclonic patients.
  • There are no adequate and well-controlled studies of piracetam during pregnancy. Piracetam is excreted in human breast milk. Therefore, piracetam should not be used during breastfeeding or breastfeeding should be discontinued, while receiving treatment with piracetam.
  • Piracetam may increase prothrombin time in patients who are on warfarin, concomitant administration with thyroid extract may cause confusion, irritability and sleep disorder. Minor inhibitory effects on CYP 2A6 and 3A4/5 can occur.
  • Most common adverse effects are haemorrhagic disorder, anaphylactoid reaction, hypersensitivity, agitation, anxiety, confusion, hallucination, nervousness, hyperkinesia and increased weight.
  • Cerebral Activators_Nootropics